Altimmune Shares Jump Premarket After Positive Results in Phase 2 Trial of Pemvidutide
By Robb M. Stewart
Altimmune's shares are set to rally at the opening bell after the biopharmaceutical company reported positive results in a study of its investigational treatment for patients with moderate-to-severe alcohol-use disorder.
In premarket trading, the shares were 9.5% higher at $3.24. That helps unwind some of the 18% drop so far this year for the stock through Monday's close.
Altimmune said it plans to request an end-of-Phase 2 meeting with the U.S. Food and Drug Administration based on the top-line results from its trial evaluating pemvidutide, a balanced glucagon/GLP-1 dual receptor agonist.
The trial met its primary endpoint with a highly statistically significant reduction in heavy-drinking days versus placebo, with consistent positive results across important secondary endpoints, including the World Health Organization risk drinking levels, zero heavy-drinking days and phosphatidyl ethanol levels.
A generally favorable tolerability profile was observed in the trial, the company said.
Chief Medical Officer Christophe Arbet-Engels said that, given the known detrimental effects of alcohol on the liver, the liver-directed impact of glucagon in pemvidutide may provide further benefit in the treatment of alcohol use disorder over GLP-1 alone, underscoring pemvidutide's promising potential.
Write to Robb M. Stewart at robb.stewart@wsj.com
(END) Dow Jones Newswires
July 28, 2026 08:29 ET (12:29 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
5 Stocks to Sell for Tax-Loss Harvesting
33 Undervalued Stocks to Buy Before the Market Shifts Again
The Smartest Moves for Bond Investors Today, and What to Do When You Have Too Many Investments
Ask the Analyst: What Is the Best Source for Low-Risk Tax-Free Income?
United States